IBA to Install Brazil's First Proton Therapy Center in Rio
IBA signed a contract on Thursday with the Fundação Severino Sombra (FUSVE), a Brazilian non-profit institution, to set up a Proteus One system in Rio de Janeiro. This project will establish Brazil's first national proton therapy center, focusing on pediatric cancer treatments.
The contract includes the provision of a Proteus One system, IBA's most advanced compact proton therapy solution. The center will be located in Barra da Tijuca, in the western area of Rio de Janeiro. The project was developed in close scientific and technical partnership with the National Cancer Institute (INCA). A roadmap for the installation of a second treatment room is also planned prospectively.
FUSVE plans to start treating patients in the first half of 2030. The contract covers the supply of the system; a multi-year agreement for operation and maintenance will be signed later.
Strengthened Strategic Presence in Latin America
Free · Every morning
Technical market signals, before the opening bell.
Bullish and bearish momentum, analyst changes, stocks to watch — automatically computed from Euronext data.
✓ Before 9 AM every morning✓ Euronext data✓ AI-powered analysis
You're in — subscription confirmed!
Your first edition is on its way. Check your spam folder and add us to your contacts.
An error occurred.
Indicative data. No investment advice. Unsubscribe at any time.
Gratuit · chaque matin
Ne ratez plus rien sur vos actions
La tendance derrière les cours. L'essentiel des valeurs Euronext en quelques minutes.
📈les valeurs en mouvement, sur la durée
🎯les objectifs d'analystes qui évoluent
📰les actualités qui font bouger les cours
tendance · 6 séances
✓ C'est fait, vous êtes inscrit !
Votre première édition arrive bientôt. Pensez à vérifier vos spams.
Une erreur est survenue.
CAC 40 · SBF 120 · données indicatives · aucun conseil en investissement · désinscription à tout moment.
This new center will be the second proton therapy facility on the continent, both utilizing IBA technology. The contract represents a strategic milestone for the Belgian company, consolidating its leadership position in proton therapy and supporting its mission to make advanced cancer treatment technologies more accessible to patients globally.
This development is part of a recent commercial growth for IBA: the group notably won a contract in mid-June with the Duke University Health System to install two Proteus One systems in North Carolina, scheduled to be operational in 2029.
Contract Price and Features
The typical selling price of a Proteus One system including a multi-year maintenance contract ranges between 35 and 45 million euros. Olivier Legrain, CEO of IBA, expressed his honor in partnering with the Fundação Severino Sombra to help make proton therapy accessible to Brazilian patients. Gustavo Oliveira do Amaral, president of FUSVE, emphasized the choice of IBA as a partner rather than just a supplier, highlighting the group's leadership, proven clinical excellence especially in pediatrics, and IBA's commitment to institutions like FUSVE.
SectorDispositifs médicaux et optique›Dispositifs médicaux
Free · every morning · before 9am
Never miss a move on your stocks
The trend behind the prices · Euronext
✓ You're in! Check your spam folder.
An error occurred.
Context
Period
Period: S1 2026
Key reported figures
Revenue: 323,7 millions d'euros
Quarterly revenue: 323,7 millions d'euros
EBITDA: 21,8 millions d'euros
EBITDA margin: 8,2 %
Net income: 9,3 millions d'euros
81 millions d'euros
Guidance from the release
Prévisions d'EBIT ajusté pour l'exercice 2026 confirmées, reflétant la confiance du Groupe dans ses perspectives pour l'ensemble de l'année.
Risks mentioned
Surcapacité persistante sur le marché d'Industrial Solutions malgré un pipeline actif.
Retards temporaires de facturation liés à la migration ERP qui ont impacté la position financière nette.
Dosimetry reste sous pression malgré les mesures de réduction des coûts.
Opportunities identified
Forte dynamique commerciale en Proton Therapy avec cinq salles vendues et cinq prises de commandes de plus de €148 millions au S1.
PanTera a obtenu la qualification de fournisseur c-GMP d'actinium-225 et extension de collaboration avec TerraPower Isotopes pour tripler la capacité de production en Belgique.
Amélioration continue de la rentabilité : marge brute passée de 29,5% à 33,7% et EBITDA ajusté en croissance de 63%.
Outlook / guidance
Management commentary: Prévisions d'EBIT ajusté pour l'exercice 2026 confirmées à au moins € 32 millions
The information presented in this article is provided for informational purposes only and does not constitute an investment recommendation, an incentive to buy or sell a financial asset, or investment advice. Readers are invited to conduct their own research before making any decision.
Investments in the stock market involve risks, including the risk of capital loss. Past performance of an asset or market is no guarantee of future results. Any investment decision should be made taking into account your personal financial situation, objectives and risk tolerance.
